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Prosthetic graft seromas is a rare complication that has been traditionally managed with open methods using partial graft
replacement and open drainage. We report the first two cases of hemodialysis graft seromas successfully treated with a
covered stent. Both patients underwent arteriovenous graft placement from the brachial artery to the axillary vein using
a standard wall, tapered 4 to 7 mm polytetrafluoroethylene graft, but developed a seroma at the arterial end of the graft.
Unsuccessful attempts were made to treat these seromas with percutaneous and open drainage. In both patients, an
8 mm  50 mm Wallgraft (Boston Scientific, Natick, Mass) was retrogradely deployed “bareback” at the arterial end of
the graft allowing for complete resolution of the graft seromas. ( J Vasc Surg 2008;48:216-7.)Graft seromas, also known as a “weeping graft”, are
often painless and may be confused with a lymphocele,
hematoma, abscess, or pseudoaneurysm.1 Fortunately, the
incidence of such seromas are rare occurring anywhere
between 0.48% and 4.2%, more commonly in upper arm
compared with forearm arteriovenous grafts.1
Numerous etiologies have been proposed to elucidate
the occurrence of graft seromas.1,2 These include manufac-
turing errors in which the grafts have excessive porosity,
technical factors in which the grafts are exposed to caustic
agents such as alcohol or iodine prior to implantation,
immunologic (or allergic) factors, and biochemical factors
such as inhibition of fibroblast growth.1,2
The Society of Vascular Surgery has recognized graft
seromas as a significant problem and devised a grading
system ranging from grade 0 to grade 3; grade 1, the most
benign, in which the seroma spontaneously resolves on its
own to grade 3, the most severe, in which the graft is
removed or bypassed.1,2
Traditional management has included observation of
the seroma, percutaneous drainage if this fails, and finally
graft removal or bypass.1-3 Successful anecdotal strategies
have been reported in which microfibrillar collagen
(Avitene) is applied to the serous portion of the graft and
plasmapheresis.1 This report describes the successful man-
agement of two upper arm hemodialysis graft seromas with
a covered stent.
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216CASE REPORTS
Case 1. One patient is a 90-year-old female who underwent
right upper extremity grafting for hemodialysis from the brachial
artery to the axillary vein using a standard wall 4 to 7 mm tapered
polytetrafluoroethylene (PTFE) (W. L. Gore & Associates, Inc,
Flagstaff, Ariz) graft. She developed a graft seroma 1 month
following placement of the graft and was unsuccessfully managed
with both percutaneous and open drainage of the seroma. Transu-
dation of fluid was seen emanating from the arterial end of the
PTFE graft. An 8 mm  50 mm Wallgraft (Boston Scientific,
Natick, Mass) was percutaneously deployed in the arterial portion
of the graft (Figs 1 and 2) and the seroma cavity was drained with
a No 7 Jackson Pratt drain. The seroma completely resolved at 2
weeks, and the graft was successfully accessed for hemodialysis at 1
month. The hemodialysis graft has remained patent for 8 months
and has been functioning well without any recurrence of the
seroma.
Case 2. The other patient is a 62-year-old female who also
underwent left upper extremity grafting from the brachial artery to
the axillary vein with a standard wall 4 to 7 mm tapered PTFE graft.
She developed a graft seroma and was managed successfully with
open drainage and placement of a No 7 JP drain. Transudation of
fluid was also seen emanating from the arterial end of the PTFE
graft. Six weeks following removal of the drain, the seroma re-
curred. An 8 mm  50 mm Wallgraft was also deployed in the
arterial portion of the graft resulting in complete resolution of the
seroma. The hemodialysis graft has remained patent for 10 months
and has also been functioning well without any seroma recurrence.
DISCUSSION
These are the first two reported cases of hemodialysis
graft seromas successfully managed with a covered stent.
Despite observation and percutaneous drainage, these se-
romas failed to resolve on their own and required definitive
treatment to allow for graft usage during hemodialysis.
Several reports have documented the successful exclu-
sion of pseudoaneurysms and other graft pathologies with
covered stents.4-6 These endovascular applications engen-
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complex, open procedures in high risk patients. Thus far,
the long-term outcome of covered stent technology for
graft pseudoaneurysm has proved to be efficacious with
regards to graft patency and hemodialysis use.4-6
It would be difficult to conjecture as to the etiology of
these two graft seromas since standard techniques during
implantation were used. Both grafts were soaked in normal
saline for 3 minutes prior to graft implantation. Both
patients had diabetes mellitus and hypertension, but nei-
Fig 1. Successful deployment of Wallgraft precisely at arterial
anastomosis.
Fig 2. Completion fistulogram demonstrating patency of arterio-
venous graft following Wallgraft deployment.ther one had congestive heart failure or fluid overload,cancer, or low albumin levels. In fact, over a 3-year period
about 75 arteriovenous grafts were placed prior to devel-
oping any graft seromas, an overall incidence of 2.5%. Both
grafts were standard wall 4 to 7 mm tapered polytetraflu-
orethylene grafts and have remained patent for 10 months
since the seromas were treated with the covered stent
without any other pathology.
Each of these graft seromas was successfully treated with
theWallgraft. TheWallgraft was retrogradely deployed “bare-
back” precisely at the arterial anastomosis. Hemostasis was
achieved with manual compression and an absorbable subcu-
taneous stitch. Several other covered stents are commercially
available and include the iCAST (Atrium Medical, Hudson,
NH), Fluency (Bard Peripheral Vascular, Tempe, Ariz), and
Viabahn (W. L. Gore & Associates, Inc, Flagstaff, Ariz).
Deployment and performance characteristics are unique to
each device, however, little is known regarding overall device
durability in the hemodialysis setting. It has generally been
accepted that the iCAST covered stent should not be used to
treat such graft seromas since it will not safely allow or tolerate
repeated punctures with a hemodialysis needle. Again, these
two hemodialysis grafts have remained patent for 10 months
despite repeated arterial needle punctures of the covered stent
portion. Durability for theWallgraft has thus far been reason-
able.
The mechanism by which covered stent deployment
minimizes and then ceases serous drainage is unclear. It
might be hypothesized, however, that the overlapping
Wallgraft interstices with the polytetrafluoroethylene pores
creates an impervious seal. Wallgraft porosity is maintained,
but completely seals the larger polytetrafluoroethylene
pores. It would be interesting to observe the resolution of
such graft seromas using a Viabahn or Fluency covered
stent.
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